Barman76 – “:this isn’t a marketing company. This is science” I...

Barman76 – “:this isn’t a marketing company. This is science”

I DON’T KNOW; it was my understanding that SI wanted to take MSB products as far as possible toward commercialisation so as to extract maximum value for the company. Further; I understood that he was very desirous of maintaining a level of control by taking of some (at least one anyway) of MSB products through to commercialisation.

The hire of Dagmar Rosa Bjorkeson as COO to head up the product launch of Ryoncil (Ryoncil/remestemcel-L, what’s the difference?) and the establishment of an efficient targeted sales force across 15 centres would appear to support MSB’s aim to become an integrated commercial organisation so a smidgin of marketing/promotion might be warranted about now. (reference announcements - Damar appointment and Aug financial results presentation).

Semi retired “Do you know even know what a double blind trial means ? look it up before you make yourself look even dumber , MSB cannot promote or advertise that the dug works during the trial”

The examples I referenced are scenarios where patients were in receipt of remestemcel-L under an EAP which I believe to be separate and independent of the current 300 patient trial that has a double bind control arm.